1. Metabolic Enzyme/Protease Apoptosis
  2. MMP Caspase Apoptosis
  3. MMP-9-IN-14

MMP-9-IN-14 是一种 MMP-9 抑制剂 (IC50 = 34.46 μM)。MMP-9-IN-14 可诱导癌细胞发生 G1 期细胞周期阻滞和 caspase 依赖性细胞凋亡 (apoptosis)。MMP-9-IN-14 可促进磷酸化 γH2AX 的积累。MMP-9-IN-14 可抑制癌细胞的迁移和侵袭,下调癌细胞中 MMP-2MMP-9 和 hTERT 的表达。MMP-9-IN-14 可在动物模型中抑制肿瘤生长及血管趋向性扩散。MMP-9-IN-14 可用于肺腺癌、宫颈癌、结直肠癌等癌症的研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

MMP-9-IN-14

MMP-9-IN-14 Chemical Structure

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

MMP-9-IN-14 is a MMP-9 inhibitor (IC50 = 34.46 μM). MMP-9-IN-14 induces G1-phase cell cycle arrest and caspase-dependent apoptosis in cancer cells. MMP-9-IN-14 promotes the accumulation of phosphorylated γH2AX. MMP-9-IN-14 inhibits the migration and invasion of cancer cells, and downregulates the expressions of MMP-2, MMP-9 and hTERT in cancer cells. MMP-9-IN-14 inhibits tumor growth and angiogenic spread in animal models. MMP-9-IN-14 can be used for the research of cancers such as lung adenocarcinoma, cervical cancer and colorectal cancer[1].

IC50 & Target

MMP-9

34.46 μM (IC50)

Caspase 3

 

Caspase-7

 

MMP-2

 

体外研究
(In Vitro)


MMP-9-IN-14 (Compound 24) (0.39-100 μM; 30 min, 37°C) 可直接抑制重组人 MMP-9 酶活性,其 IC50 为 34.46 μM[1]

MMP-9-IN-14 (0-50 μM;72 h) 抑制多种细胞系 (A-549,H-226,H-460,HCT-116,Hep G2,HeLa,HaCaT , MRC-5) 的活力,IC50 值分别为 2.23,2.34,,5.49,4.95,51.41,2.75,8.89,18.47 μM[1]
MMP-9-IN-14 (2.23 μM; 24-72 h) 可在 A-549 细胞中诱导 G1 期细胞周期阻滞[1]
MMP-9-IN-14 (2.23 μM; 24-72 h) 可诱导 A-549 细胞发生 caspase 依赖性细胞凋亡[1]
MMP-9-IN-14 (2.23 μM; 24-72 h) 在 A-549 细胞中增加 γH2AX 阳性细胞数量,累积 DNA 损伤[1]
Compound 24 (5-30 μM; 0-24 h) 抑制 A-549 癌细胞的迁移和侵袭[1]
Compound 24 (15-30 μM; 48 h) 下调 A-549 细胞中转移相关基因 (MMP-2, MMP-9) 和 hTERT 的表达,并能强效抑制 TGF-β1 诱导的 MMP 表达[1]
Compound 24 (10-50 μM; 72 h) 抑制 A-549 3D 球状体的增殖,在具有生理相关性的 3D 模型中展现出抗转移活性[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: A-549,H-226,H-460,HCT-116,Hep G2,HeLa,HaCaT , MRC-5 cells
Concentration: 0-50 μM
Incubation Time: 72 h
Result: Inhibited the viability of various cell lines (A-549, H-226, H-460, HCT-116, Hep G2, HeLa, HaCaT, MRC-5), with IC50 values of 2.23, 2.34, 5.49, 4.95, 51.41, 2.75, 8.89, and 18.47, respectively.

Cell Cycle Analysis[1]

Cell Line: A-549 cells
Concentration: 2.23 μM
Incubation Time: 24 h, 48 h, 72 h
Result: Caused a significant decrease in the S-phase population after 24 h treatment. Induced cell accumulation in the G1 phase with a reduction in G2/M content by 48 h treatment.
Induced a marked G1-phase arrest, with ~65% of cells in G1 phase and concurrent reductions in S and G2/M fractions at 72 h treatment.

Apoptosis Analysis[1]

Cell Line: A-549 cells
Concentration: 2.23 μM
Incubation Time: 24 h, 48 h, 72 h
Result: Caused a increase in apoptosis, with ~10% early apoptotic and ~8% late apoptotic cells after 24 h treatment.
Increased early apoptosis to ~11% and late apoptosis to ~15%, with ~70% cell viability remaining at 48 h treatment.
Increased caspase-3/7 activity by ~5-fold at 24 h, ~5-6-fold at 48 h, and ~7-fold at 72 h compared to controls.

Cell Migration Assay [1]

Cell Line: A-549 cells
Concentration: 5, 10, 15 μM
Incubation Time: 0 h, 6 h, 12 h,
18 h, 24 h
Result: Significantly and in a concentration-dependent manner inhibited cell migration and delayed wound closure.

Cell Invasion Assay[1]

Cell Line: A-549 cells
Concentration: 15, 30 μM
Incubation Time: 24 h
Result: Reduced the number of invading A-549 cells to ~65% of control levels at 15 μM. Reduced the number of invading cells to ~25% of control levelsat 30 μM.

Real Time qPCR[1]

Cell Line: A-549 cells (with or without TGF-β1 stimulation)
Concentration: 15, 30 μM
Incubation Time: 48 h
Result: Significantly suppressed TGF-β1-induced MMP-2 and MMP-9 mRNA expression: at 15 μM, MMP-2 expression was reduced by ~60% and MMP-9 by ~70% ; at 30 μM, both MMP-2 and MMP-9 mRNA levels were reduced to near baseline. Downregulated hTERT expression: at 15 μM, hTERT expression was reduced by ~50%, and at 30 μM, was almost undetectable.
体内研究
(In Vivo)

MMP-9-IN-14 (compound 24) (25-50 μM; 局部给药;单次给药) 可抑制鸡胚尿囊膜 (CAM) 上 A-549 肿瘤生长,并可完全抑制肿瘤细胞的血管趋向性播散,且未检测到胚胎毒性[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: A-549 Xenotransplantation chorioallantoic membrane (CAM) model[1]
Dosage: 25 μM; 50 μM
Administration: topical; single administration
Result: Reduced median tumour area. Showed weaker, less homogeneous CellTracker Green signals in treated tumours, indicating reduced tumour cell viability/density.
Revealed a near-complete absence of disseminated fluorescent tumour cells in distal CAM regions, compared to frequent vasculotropic spread in vehicle controls.
分子量

481.39

Formula

C25H18Cl2N2O2S

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
参考文献
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
MMP-9-IN-14
目录号:
HY-181272
需求量: